source
- Boehringer Ingelheim pauses phase 1 trial of BI 3031185 in Japan to investigate safety eventBoehringer Ingelheim has placed a phase 1 study of its investigational oral small‑molecule candidate BI 3031185 on voluntary hold after a safety event was reported. The trial, which began in early…
- Epic expands AI tools for clinicians and patients, intensifying competition for health-tech startupsEpic highlighted its growing portfolio of artificial‑intelligence applications for both clinicians and patients at its annual Users Group Meeting in Verona, Wisconsin. The presentation showcased ne…